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Introduction
In 2010, the photomotor response (PMR) of zebrafish 
embryos was reported for the first time as a robust behavior 
that allows high-throughput neuroactive drug discovery.1 
This study by Kokel and colleagues thoroughly character-
ized the PMR as a stereotypic series of motor behaviors by 
zebrafish embryos in response to high-intensity light pulses. 
The potential of a PMR-based behavioral assay was demon-
strated in a chemical screen of 14,000 small molecules, 
identifying hundreds of PMR-modifying hits. As PMR is 
regulated by multiple neurotransmitter pathways, PMR-
modifying molecules are considered to be neuroactive. 
Interestingly, PMR behavior was also proven to allow target 
identification of novel hits by co-clustering of molecules 
with similar phenotypes and with known mechanism of 
action (MOA).1 This characteristic of PMR can have a 
broad applicability when generating a large reference map 
of PMR phenotypes of small molecules with known MOA. 
Then, the MOA of an interesting hit or drug candidate can 
be predicted by co-clustering and a targeted approach of 
mechanistic investigation can be done. However, little is 
known about the predictive value of PMR phenotyping. 
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Abstract
Recently, the photomotor response (PMR) of zebrafish embryos was reported as a robust behavior that is useful for 
high-throughput neuroactive drug discovery and mechanism prediction. Given the complexity of the PMR, there is a need 
for rapid and easy analysis of the behavioral data. In this study, we developed an automated analysis workflow using the 
KNIME Analytics Platform and made it freely accessible. This workflow allows us to simultaneously calculate a behavioral 
fingerprint for all analyzed compounds and to further process the data. Furthermore, to further characterize the potential 
of PMR for mechanism prediction, we performed PMR analysis of 767 neuroactive compounds covering 14 different 
receptor classes using the KNIME workflow. We observed a true positive rate of 25% and a false negative rate of 75% in 
our screening conditions. Among the true positives, all receptor classes were represented, thereby confirming the utility of 
the PMR assay to identify a broad range of neuroactive molecules. By hierarchical clustering of the behavioral fingerprints, 
different phenotypical clusters were observed that suggest the utility of PMR for mechanism prediction for adrenergics, 
dopaminergics, serotonergics, metabotropic glutamatergics, opioids, and ion channel ligands.
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Which neurological pathways can modify the PMR in a 
robust and distinct manner has only been characterized in 
part, and there has been no characterization of pathways 
that cannot. There has also been no characterization of the 
rate of false negatives. Thus, there is a need to further char-
acterize the predictive value of the PMR.
PMR is a very complex behavior to analyze, and data are 
generated rapidly by video recording. Motion is recorded as a 
change in pixels continuously in time for 30 s for each well of 
a 96-well plate. In our setup, a time frame of 0.067 s was used. 
This implies that for each well, 448 data points are generated in 
30 s. As replicate wells are used per condition and in case of 
screening, hundreds—up to thousands—of molecules are ana-
lyzed, an excess of data is rapidly generated. For example, this 
study resulted in more than 1.5 million data points for the anal-
ysis of only 767 compounds. Hence, there is a need for rapid 
and easy analysis of the behavioral data.
In this study, we developed an automated workflow for 
PMR analysis using the KNIME Analytics Platform (http://
www.knime.org).2 This is an open-source integration plat-
form providing a powerful and flexible workflow system 
combined with data analytics, visualization, and reporting 
capabilities. KNIME integrates nodes for machine learning, 
statistical data analysis, and interfaces to various scripting 
languages, for example, the statistical programming lan-
guage R. KNIME’s functionality can be extended with 
nodes provided via an online repository (the so-called 
KNIME extensions). Our automated analysis workflow 
allows simultaneous calculation of a behavioral fingerprint 
for all analyzed molecules and further processing of the 
data, for example, by hierarchical clustering. Since the 
workflow has broad utility for behavioral analysis, it is 
made freely accessible on the KNIME Public Example 
Server as 050_Applications/050021_PMR Analysis.
Furthermore, to further characterize the potential of the 
PMR for mechanism prediction, we performed PMR analy-
sis of 767 neuroactive compounds covering 14 different 
receptor classes (adrenergics, dopaminergics, serotoner-
gics, opioids, sigma ligands, cholinergics, histaminergics, 
melatonin ligands, ionotropic glutamatergics, metabotropic 
glutamatergics, GABAergics, purinergics, adenosines, and 
ion channel ligands) using the KNIME workflow. Our results 
confirm the utility of the PMR assay to identify a broad range 
of neuroactive molecules. Moreover, the observations suggest 
that PMR can be useful for mechanism prediction for adrener-
gics, dopaminergics, serotonergics, metabotropic glutamater-
gics, opioids, and ion channel ligands.
Materials and Methods
Zebrafish Maintenance
Adult zebrafish (Danio rerio) stocks of the AB strain 
(Zebrafish International Resource Center, Eugene, OR) 
were maintained at 28.0 °C, on a 14/10 h light/dark cycle 
under standard aquaculture conditions. Fertilized eggs were 
collected via natural spawning. Embryos and larvae were kept 
on a 14/10 h light/dark cycle in embryo medium: 1.5 mM 
HEPES, pH 7.6, 17.4 mM NaCl, 0.21 mM KCl, 0.12 mM 
MgSO4, and 0.18 mM Ca(NO3)2 in an incubator at 28.0 °C. All 
zebrafish experiments carried out were approved by the Ethics 
Committee of the University of Leuven (Ethische Commissie 
van de KU Leuven, approval no. P101/2010) and by the 
Belgian Federal Department of Public Health, Food Safety and 
Environment (Federale Overheidsdienst Volksgezondheid, 
Veiligheid van de Voedselketen en Leefmilieu, approval no. 
LA1210199).
Compound Libraries and Compounds
A total of 633 compounds from the Screen-Well Neurotransmitter 
Library (BML-2810-0100, Enzo Life Sciences, Farmingdale, 
NY), 71 compounds from the Screen-Well Ion Channel Ligand 
Library (BML-2805-0100, Enzo Life Sciences), 33 selected 
compounds from the Spectrum Collection Library (MicroSource 
Discovery Systems, Inc., Gaylordsville, CT), and 30 individu-
ally purchased compounds (Sigma-Aldrich, Prestwick, St. 
Louis, MO) were analyzed by the PMR assay. Positive controls 
isoproterenol and apomorphine were purchased from Sigma-
Aldrich, and diazepam was obtained from the pharmacy 
(Roche, Basel, Switzerland; valium 10 mg/2 mL ampullas).
Compound Preparation
Isoproterenol, diazepam, and apomorphine were dissolved 
in DMSO to 10, 5, 2.5, and 1.25 mM concentrations and 
100-fold diluted in the embryo’s swimming water (embryo 
medium) to final concentrations of 100, 50, 25, and 12.5 
µM with a final solvent concentration of 1% DMSO. A total 
of 767 compounds were analyzed by the PMR assay at a 
concentration of 50 µM with a final solvent concentration 
of 0.5% or 1% DMSO. A total of 737 compounds were pro-
vided by compound libraries as 10 mM DMSO stocks 
(water was used as a solvent for DMSO insoluble com-
pounds) and 200-fold diluted in the embryo’s swimming 
water to final concentrations of 50 µM (0.5% DMSO). 
Thirty individually purchased compounds were prepared as 
5 mM DMSO stocks and 100-fold diluted in the embryo’s 
swimming water to final concentrations of 50 µM (1% 
DMSO). Vehicle (VHC)-treated controls were treated with 
0.5% DMSO, 1% DMSO, or water in accordance with the 
final solvent concentration of the analyzed compounds.
Photomotor Response Assay
Protocol was adapted from Kokel and colleagues.1 The pho-
tomotor response of zebrafish embryos was investigated by 
automated behavioral tracking (Zebrabox, ViewPoint, 
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Lyon, France) at 30–32 h postfertilization (hpf). Zebrafish 
embryos were placed in a 96-well plate in embryo medium 
at 27–29 hpf (prim-15 stage), followed by a dark incubation 
of 3 h with VHC or compound prior to tracking, including 
20 min of habituation in the Zebrabox chamber. Concurrent 
controls were run with each compound to avoid interplate 
variation. Exactly five embryos were placed per well to 
obtain a cumulative photomotor response. Total motion was 
recorded for 30 s at 15 frames per second (fps) in fully dark 
conditions with a high-intensity light pulse (5.2 mW/cm2, 
38,000 lux) given at 10 and 20 s lasting 1 s. Raw data of 
total movement per well were used and are defined as the 
sum of all image pixel changes detected during the time 
interval of 0.067 s, corresponding to one frame. Total 
motion was plotted in function of time, and average motion 
was plotted per time period. The PMR was divided into 
eight time periods. The so-called prestimulus phase, at 
which embryos show basal activity, was considered one 
time period (PRE, seconds 0–10). The latency phase, which 
occurs immediately after the first light stimulus, was con-
sidered one period (L, seconds 10–11). The excitatory 
phase, at which embryos shake vigorously, was divided into 
three periods (E1, seconds 11–13; E2, seconds 13–16; E3, 
seconds 16–20). Finally, the refractory phase, at which 
embryos show a lower-than-basal activity, is triggered by 
the second light stimulus and was divided into three periods 
as well (R1, seconds 20–22; R2, seconds 22–25; R3, sec-
onds 25–30). For control experiments with isoproterenol, 
diazepam, and apomorphine, data were pooled from three 
independent experiments with four to six replicate wells per 
condition. For screening of neuroactive molecules, data 
were pooled from three or six replicate wells per molecule. 
Replicate wells were scattered over the 96-well plate. The 
PMR assay was standardized for temperature at 28 °C, 
including habituation and behavioral tracking in the 
Zebrabox, which was placed in an incubator for tempera-
ture control. Automated behavioral tracking was standard-
ized for light intensity by the usage of only the 30 central 
wells of a 96-well plate, ensuring identical light intensity 
regardless of the position.
Microscopic Evaluation of Toxicity
The PMR assay was immediately followed by visual eval-
uation of the embryos by a light microscope to assess tox-
icity of pharmacological treatment. Overall morphology, 
heartbeat, and touch response were investigated. Overall 
morphology was considered normal in case of a normal 
appearance. Overall morphology was considered abnormal 
in case of signs of necrosis, which was especially seen at the 
tip of the tail. We did not encounter other morphological 
abnormalities such as edema or developmental defects. The 
heartbeat was considered normal, reduced, or absent. The 
behavioral response of embryos to touch was investigated 
by touching the chorion of the embryo at the site of the yolk 
with a bold needle. Touch response was considered normal 
(including hyperactivity), reduced, or absent. Compounds 
were scored as normal (N) if exposed embryos had a normal 
morphology, heartbeat, and touch response. Compounds 
were scored as sedative (S) if exposed embryos had a 
normal morphology, normal or reduced heartbeat, and a 
reduced or absent touch response. Compounds were scored 
as toxic (T) if exposed embryos had an abnormal morphol-
ogy or an absent touch response with absence of heartbeat.
Behavioral Fingerprints
Behavioral fingerprints were calculated by an automated 
workflow using KNIME Analytics Platform 2.11.3. A 
behavioral fingerprint represents the embryonic motion 
during the eight PMR periods by subsequent numeric val-
ues. Each period was described by the first (25% of motion, 
Q1) and third (75% of motion, Q3) quantile, giving a total 
of 16 numeric values. For comparison with VHC-treated 
embryos, pseudo Z-scores were calculated for each log-
transformed quantile by the following formula:
pseudo Z – score = 
 mtreatment – mcontrol
                                         σcontrol
The mean value (µ) of the control condition is subtracted 
from the mean value of the treatment condition, and the 
result is divided by the standard deviation (σ) of the control 
condition to obtain the pseudo Z-score. The behavioral fin-
gerprints consist of 16 subsequent pseudo Z-scores, calcu-
lated from the Q1 and Q3 from each PMR period. The 
definition and calculation of behavioral fingerprints or bar-
codes are adapted from Kokel and colleagues.1,3
KNIME Analytics Platform
Supplemental Figure S1 shows the main window of the 
KNIME Analytics Platform. On the left, the “KNIME 
Explorer” shows the available workflows. The “Node 
Repository” contains the available nodes. In the center, an 
open workflow is shown. A description of the selected node 
is given at the right of the window. The “Console” is seen at 
the bottom, which gives details about warnings and errors 
that occurred during workflow execution (Suppl. Fig. S1).
A KNIME workflow is composed of multiple nodes that 
are connected by ports. Data are passed along the connec-
tions between ports in a table structure with columns (each 
having a certain type) and rows. The parameters of nodes 
and their documentation are available via a configuration 
dialog. More complex workflows, such as the one we devel-
oped and describe below, also contain loops and switches. 
Loops allow applying the same series of nodes to multiple 
input files one at a time, and switches allow executing only 
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certain branches of the workflow based on user-defined 
conditions. To further structure a workflow, KNIME pro-
vides the so-called metanodes to group a collection of 
nodes. Grouping into metanodes can be used to hide a com-
plex series of nodes and instead provide a high-level view 
on the data flow.
Results
PMR Analysis of Positive Controls Isoproterenol, 
Diazepam, and Apomorphine
To validate our optimized PMR assay, three drugs with 
known PMR-modifying effects were analyzed: isoprotere-
nol, diazepam, and apomorphine. These drugs were earlier 
shown by Kokel and colleagues to cause excitation, inhibi-
tion, and latency of the excitatory phase, respectively.1
Embryos incubated for 3 h with 100 µM isoproterenol 
demonstrated an overall excitation of the photomotor 
response in comparison with VHC-treated controls. This 
increase in motion was observed to be significant at the pre-
stimulus phase (p < 0.01), latency phase (p < 0.05), and first 
(p < 0.001) and second (p < 0.05) excitation periods (Fig. 
1A,B). Embryos incubated for 3 h with 100 µM diazepam 
demonstrated an overall inhibition of the PMR in compari-
son with VHC-treated controls. This decrease in motion 
was observed to be significant at the prestimulus phase (p < 
0.001), latency phase (p < 0.01), and first (p < 0.001) and 
second (p < 0.001) excitation periods (Fig. 1C,D). Finally, 
embryos incubated for 3 h with 100 µM apomorphine dem-
onstrated a complex altered PMR in comparison to VHC-
treated embryos. The PRE motion was lowered, no 
difference was seen in the E1 period, and a significant 
increase in motion was observed for the E2 (p < 0.001), E3 
Figure 1. PMR of 30–32 hpf 
zebrafish embryos incubated with 
positive controls isoproterenol, 
diazepam, and apomorphine. Embryos 
were treated for 3 h with vehicle 
(VHC) or drug. (A-F) Total motion 
and mean motion of embryos treated 
with VHC or 100 µM of drug. (A, C, 
E) Total motion of the embryos as 
a function of time. (B, D, F) Mean 
motion of the embryos as a function 
of eight PMR periods. (G) Mean 
behavioral fingerprints of embryos 
treated with 12.5, 25, 50, and 100 
µM of isoproterenol, diazepam, and 
apomorphine, respectively. (B, D, 
F) Data are expressed as mean ± 
SEM. Statistical analysis was done by 
two-way ANOVA (GraphPad Prism 
5). Significance levels: *p < 0.05, **p < 
0.01, ***p < 0.001.
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(p < 0.001), and R1 (p < 0.01) periods. These latter observa-
tions were due to the occurrence of a second excitation 
peak, delayed to the incidence of the first excitation peak. 
This excitation peak only slowly passed in comparison with 
the normal excitation peak of control embryos (Fig. 1E,F). 
Concentration dependency was observed for all phenotypes 
(Fig. 1G). Taken together, these observations suggest that 
our PMR assay can detect PMR-modifying effects very 
similar to those reported by Kokel and colleagues.
Generation of an Automated KNIME Workflow 
for Large-Scale PMR Analysis
For our large-scale PMR analysis of neuroactive molecules, 
behavioral analysis had to be rapid, easy, and automated. 
Therefore, a KNIME workflow was built to analyze the data 
recorded by the Zebrabox. It computes the pseudo Z-scores 
and behavioral fingerprints for each molecule, and finally per-
forms hierarchical clustering of the pseudo Z-scores and gen-
erates a dendrogram. The workflow is rather complex, as it 
performs all steps, from reading the raw data until the final 
dendrogram. In order to make it more readable, it has been 
divided into several sections using the metanode concept men-
tioned in Materials and Methods. The workflow is shown in 
Figure 2. For reasons of space, we will only highlight the 
important parts. The complete workflow, including inline 
comments, can be downloaded from KNIME’s Public Example 
Server directly from within KNIME (login via the entry in the 
“KNIME Explorer” view).
The workflow requires two types of input. The first input 
is the raw data, which consists of several CSV files (one per 
96-well plate) containing raw measurements for all wells on 
the plate over the 30 s interval (about 28,000 rows per file). 
The data are divided into three columns: time, well ID (e.g., 
c1 and c2), and embryonic motion measurement. The work-
flow iterates over all files in the experiment’s directory and 
computes the behavioral fingerprint for each molecule (see 
below). The second input is a file that contains a mapping 
between the plates/wells and the treatment in each well 
(referred to as substance in the workflow), for example, 
VHC or a certain molecule. Additionally, it may contain 
manual annotations, indicating whether a well should be 
ignored in the further analysis, for example, because the 
well was empty or no treatment was added.
Computation of the behavioral fingerprints inside the 
“Calculate fingerprint” metanode works as follows (Fig. 3A). 
First, the raw input data are transformed from the three-column 
structure described above into a table with a column for each 
well and a row for each time point (“Data Transformation” 
metanode). The values in the cells are the measurements. The 
“Unify Domains” metanode ensures that the y axes in the line 
plots have the same scales and can therefore be directly com-
pared. Figure 3B shows some plots generated by the “Line 
Plots” metanode. The Numeric Binner assigns names to the 
time intervals (“segments”) as described above (e.g., L, E1, 
and R1). The “Group Loop” iterates over the measurements in 
each of the segments separately. For each well/substance in 
each segment, we compute the 25% and 75% quantiles (Q1 
Figure 2. KNIME workflow for PMR analysis. The workflow structure is using metanodes in order to make it more readable and 
easier to maintain.
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and Q3, respectively) and use the logarithms of these values in 
subsequent steps (“Calculate Quartiles” metanode). Figure 3C 
shows parts of the resulting table for segment R3. Finally, we 
compute the pseudo Z-scores based on the quartiles of the con-
trols and the molecules, and transform the structure to obtain a 
row for each segment and a pseudo Z-score (Q1 and Q3) with 
the corresponding values for each molecule in the columns 
(Fig. 3D). This is the result of the outermost loop, which com-
pletes the computation of all values for all plates. Note also the 
“Check bad measurements” metanode in the center of Figure 
3A. This node provides an extra internal control to avoid the 
analysis of a plate when multiple control wells are ignored due 
to an error, for example, a software error or manual error. It 
checks the manual annotations for all wells, and if such a plate 
occurs, it fails and will stop execution of the remaining 
workflow.
The next step is to remove all columns/molecules with 
pseudo Z-scores below a certain threshold. The threshold 
can easily be set by the user via the configuration dialog of 
the “Filter substances” metanode, without having to know 
the other details of the filtering.
In the bottom part of the main workflow (Fig. 2), we first 
transpose the table so that each molecule is in a row and the 
pseudo Z-scores for the segments are in the columns. Next, 
we remove the segment “IGNORE” that represents seconds 
just before and after the 30 s PMR period that are not taken 
into account. Then we compute a distance matrix (Euclidean 
distance) using the pseudo Z-scores as dimensions and per-
form hierarchical clustering with complete linkage. The 
final result is a dendrogram, including a heatmap, as shown 
in Figure 4 and discussed in the next sections.
PMR Analysis of 14 Classes of Neuroactive 
Molecules
A systematic analysis was done of 767 neuroactive molecules 
covering 14 different receptor classes (adrenergics, dopami-
nergics, serotonergics, opioids, sigma ligands, cholinergics, 
histaminergics, melatonin ligands, ionotropic glutamatergics, 
metabotropic glutamatergics, GABAergics, purinergics, aden-
osines, and ion channel ligands) to further characterize the 
neurological pathways that can alter PMR. Embryos were 
incubated either with vehicle (0.5 or 1% DMSO) or with 50 
µM of a certain molecule (final solvent concentration of 0.5 or 
1% DMSO) for 3 h prior to PMR analysis. PMR analysis was 
followed by microscopic evaluation of embryo morphology, 
Figure 3. A detailed view of the metanode that computes the behavioral fingerprints. (A) Inside view of the metanode “Calculate 
fingerprint for plate”. The metanode is again divided into several nested metanodes. (B) Result table of the metanode “Line Plots”. 
Line plots show the embryonic motion in time in a certain well. (C) Result table of the metanode “Calculate Quartiles” showing some 
computed quantiles for segment R3. (D) Final result table showing the pseudo Z-scores for tested molecules.
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heartbeat, and touch response, to assess toxicity of pharmaco-
logical treatment. A low rate of sedative (3.4%) and toxic 
(2.2%) compounds was observed, suggesting that 50 µM of 
most neuroactive compounds is well tolerated by zebrafish 
embryos during an acute exposure (Table 1).
A PMR positive molecule was defined as a molecule that 
modifies the photomotor response such that its behavioral 
fingerprint contains at least one pseudo Z-score with an 
absolute value exceeding 3. At this critical value, 195 mol-
ecules were observed to be PMR positive, giving a true 
positive rate of 25.4% and a false negative rate of 74.6%. 
Thus, 25.4% of known neuroactive molecules alter PMR 
sufficiently at the analyzed concentration to be identified as 
neuroactive by the PMR assay. At a lower critical value of 
2, 324 molecules were PMR positive, giving a true positive 
rate of 42.2% and a false negative rate of 57.8%. This lower 
stringency allows the detection of more than 40% of the 
neuroactive molecules at 50 µM. At a higher critical value 
of 5, 117 molecules were still observed to be positive, giv-
ing a true positive rate of 15.3% and a false negative rate of 
84.7% (Table 1). These PMR positives alter the PMR so 
much that a difference in motion of at least five times the 
standard deviation of the control is seen. For further analy-
sis, the critical value of 3 was taken to consider only neuro-
active molecules that alter PMR in a robust manner.
Among PMR positive molecules, all neurological path-
ways are represented as molecules from all receptor classes 
were included. This observation confirms the utility of 
PMR to detect a broad range of neuroactive molecules and 
suggests the involvement of these pathways in PMR 
regulation.
Hierarchical Clustering of PMR Positive 
Molecules
To characterize the classes of neuroactive molecules that 
can induce a distinct PMR phenotype, hierarchical cluster-
ing of behavioral fingerprints of the 195 PMR positive mol-
ecules was done (Fig. 4). A cluster was considered to be 
enriched with molecules from a certain neurological path-
way if more than one-third of the molecules belong to a 
single receptor class and the cluster has a minimum size of 
seven fingerprints. This was determined in a top-down 
Table 1. PMR Analysis of Neuroactive Compounds.
Number of  
Molecules Rate (%)  
Total 767  
Normal (N) 724 94.4  
Sedative (S) 26 3.4  
Toxic (T) 17 2.2 Toxicity rate
Pseudo Z-score ≥ |2|
 Positives 324 42.2 True positive rate
 Negatives 443 57.8 False negative 
rate
Pseudo Z-score ≥ |3|
 Positives 195 25.4 True positive rate
 Negatives 572 74.6 False negative 
rate
Pseudo Z-score ≥ |5|
 Positives 117 15.3 True positive rate
 Negatives 650 84.7 False negative 
rate
Figure 4. Hierarchical clustering 
of PMR positive molecules. 
Behavioral fingerprints of PMR 
positive molecules were clustered 
by complete linkage of the distance 
matrix (Euclidean distance). (A) 
Heatmap and dendrogram are 
shown. Numbers 1–8 indicate 
clusters that are enriched with 
molecules from a single receptor 
class. (B) Color scales of the 
heatmap are given for the first (Q1) 
and third (Q3) quantiles for all PMR 
periods. PRE, prestimulus phase; L, 
latency phase; E1, excitatory period 
1; E2, excitatory period 2; E3, 
excitatory period 3; R1, refractory 
period 1; R2, refractory period 2; 
R3, refractory period 3.
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approach evaluating the 30 most distinct clusters of the 
heatmap, as indicated by the workflow. Eight clusters were 
observed to be enriched with a certain class of molecules. 
These clusters are indicated by numbers 1–8 in Figure 4.
Cluster 1 is enriched with behavioral fingerprints from 
opioids. Five out of seven molecules are opioid receptor 
ligands. These show a higher activity in the E1 and E2 
period in comparison to control behavior and a reduced 
activity in periods E3, R1, R2, and R3 (cluster 1; Suppl. 
Fig. S2). Cluster 2 is enriched with ligands from metabo-
tropic glutamatergic receptors. Four out of 10 molecules 
belong to this class of receptors; 3 of them are receptor ago-
nists. These molecules show a behavioral fingerprint with 
decreased activity mainly in periods E2 and E3, but also in 
R1–R3 (cluster 2; Suppl. Fig. S2). Cluster 4 is also enriched 
with ligands from metabotropic glutamatergic receptors, 
but all are receptor antagonists. Four out of nine molecules 
belong to this class of receptors and show a reduced activ-
ity, especially in the PRE, E1, and E2 periods, in compari-
son to controls (cluster 4; Suppl. Fig. S2). Three of these 
molecules have the mGlu5 receptor as target. Cluster 3 is 
enriched with ligands from adrenergic receptors. Ten out of 
23 molecules belong to this class of receptors; 8 of them are 
receptor agonists and 7 molecules are α receptor ligands. 
They show a behavioral fingerprint with an overall increased 
activity in comparison to controls (cluster 3; Suppl. Fig. 
S2). Cluster 5 is enriched with ligands from dopaminergic 
receptors. Six out of eight molecules belong to this receptor 
class; five of them are receptor agonists. Their behavioral 
fingerprints show a decreased activity, especially in the 
PRE and E1 phases (cluster 5; Suppl. Fig. S2). Cluster 8 is 
also enriched with ligands from dopaminergic receptors. 
Eleven out of 29 molecules belong to this class of receptors, 
both agonists and antagonists. Six of them are D4 receptor 
ligands. Their behavioral fingerprints also show a decreased 
activity in the PRE phase, but in comparison to cluster 5, the 
activity in the E1 period is much more decreased (cluster 8; 
Suppl. Fig. S2). Cluster 6 is enriched with behavioral fin-
gerprints from different types of ion channel ligands. 
Twelve out of 33 molecules belong to this type of ligands, 
and 8 of them act on calcium channels. Their behavioral 
fingerprints show a decreased motion during the E1 and E2 
periods and a moderate decrease or increase in motion in 
periods E3-R3 (cluster 6; Suppl. Fig. S2). Finally, cluster 7 
is part of cluster 6. This smaller cluster is also enriched with 
ligands from serotonergic receptors. Five out of 13 mole-
cules belong to this receptor class. Their behavioral finger-
prints are very similar to those from cluster 6, but this subset 
shows a more decreased activity in the E1 and E2 periods 
(cluster 7; Suppl. Fig. S2).
In summary, ligands from the following classes of recep-
tors were observed to induce a distinct PMR phenotype: 
adrenergics, dopaminergics, serotonergics, metabotropic 
glutamatergics, opioids, and ion channel ligands. This 
means that sigma ligands, cholinergics, histaminergics, 
melatonin ligands, ionotropic glutamatergics, GABAergics, 
purinergics, and adenosines seem to fail to induce a distinct 
PMR phenotype despite their strong PMR-modifying 
effects. These data suggest that PMR is useful for mecha-
nism prediction only within the above first mentioned neu-
rological pathways.
Discussion
With this study, a systematic PMR analysis was done of the 
different neurological pathways by analysis of 767 ligands 
that cover 14 receptor classes. Our results confirm the utility 
of the PMR assay to identify a broad range of neuroactive 
molecules, as was demonstrated by Kokel and colleagues.1 
The use of the PMR for mechanism prediction was further 
investigated and is suggested to be limited to adrenergics, 
dopaminergics, serotonergics, metabotropic glutamatergics, 
opioids, and ion channel ligands. Our data thereby confirm the 
study by Kokel and colleagues, who also reported phenotypi-
cal clusters for adrenergic and dopaminergic agonists.1 
Furthermore, we expand their findings with the report of dis-
tinct phenotypical clusters for serotonergics, metabotropic 
glutamatergics, opioids, and ion channel ligands. In contrast 
to the study by Kokel, we did not identify a cluster enriched 
with adenosine receptor antagonists. This is likely due to 
differences in protocol, for example, incubation time (3 h 
vs. 2–10 h), but can also be due to the more sensitive detec-
tion of embryonic motion by our setup (detection of motion 
in the entire well vs. detection of motion at six lines cover-
ing the well).
The identification of phenotypic clusters from adrener-
gics, dopaminergics, serotonergics, metabotropic glutama-
tergics, opioids, and ion channel ligands suggests that 
within these classes new molecules can be identified and 
the mechanism can be predicted by phenotypic similarity. 
This allows the use of PMR not only to screen for neuroac-
tivity in general, but also to screen for a certain class of 
ligands, indicating their potential therapeutic use. Our data 
suggest that this is not possible for all neurological path-
ways, but is limited to the receptor classes mentioned above. 
Concerning the detail of mechanism prediction, an indica-
tion for agonistic or antagonistic activity is clear in four of 
the eight clusters, but an indication for a specific target or 
receptor is not so common. In our data set, only four targets 
were highly present in their respective clusters, that is, the 
mGlu5 receptor, α receptor, calcium channel, and D4 recep-
tor. This is not surprising, as the annotated activity of a mol-
ecule will not always reflect its activity on the zebrafish 
target. This is due to possible differences between zebrafish 
and human receptors and is referred to as the zebrafish 
annotation problem.4 Nevertheless, PMR phenotyping can 
be used for target prediction when screening for molecules 
without a predefined target. This is suggested by our data 
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and was already demonstrated by Kokel and colleagues, 
who identified novel acetylcholinesterase inhibitors by phe-
notypic similarity.1
The absence of phenotypic clusters from the other classes 
of ligands is due to the absence of distinct PMR phenotypes 
for each class and can have multiple causes. First, ligands 
from different classes can (in)directly affect the same PMR-
regulating neurological pathway or affect different neuro-
logical pathways with a similar PMR-modifying effect. 
Second, there can be a large variation between ligands from 
the same receptor class in terms of conservation of the drug 
target in zebrafish, optimal test concentration, or drug 
absorption, which all can result in different PMR pheno-
types. Third, as many neuroactive ligands have multiple 
targets, it is possible that these ligands do not induce a simi-
lar PMR phenotype within a certain class.
Furthermore, we observed a high false negative rate for 
PMR analysis at the analyzed concentration of 50 µM and 
after an acute exposure of 3 h. Analysis of multiple concen-
trations and exposure times will increase the number of true 
positives, but this will also largely reduce the throughput. 
Moreover, as many neuroactive drugs act on multiple tar-
gets, it can be expected to detect less specific behavioral 
fingerprints when analyzing compounds at high concentra-
tions. Therefore, ideally, a concentration–response analysis 
should be performed for each compound to allow improved 
clustering of the fingerprints based on cross-concentration 
behavioral similarities within receptor classes. Such an 
approach not only would reduce the false negative rate, but 
also could improve phenotype-based mechanism predic-
tion. Besides the analysis of compounds at a single concen-
tration and exposure time, other causes for the observation 
of false negatives in this study could be malabsorption of 
the drug, failure of the immature metabolism to activate 
prodrugs, absence of the functional target in zebrafish or in 
the immature brain, or the drug target not being involved in 
PMR regulation.
For improved understanding of our results, it is impor-
tant to know which neurological pathways are present in the 
immature brain of the zebrafish embryo. The PMR occurs 
between 30 and 40 hpf, while the light-evoked refractory 
phase is already observed from 27 hpf onward.5 At these 
stages, primary neurogenesis is ongoing until 48 hpf, when 
secondary neurogenesis initiates. Primary neurogenesis 
involves the transient establishment of an early sensorimo-
tor circuit that allows motor behaviors. These neurons were 
reported to include glutamatergic, GABAergic, cholinergic, 
and glycinergic neurotransmission at 24 hpf.6–8 Furthermore, 
spatiotemporal expression of aminergic innervation in the 
developing zebrafish embryo demonstrated dopaminergic, 
(nor)adrenergic, and serotonergic neurotransmission at 24 
hpf. Adrenergic or noradrenergic neurons were observed in 
the hindbrain in the developing locus coeruleus and also by 
36 hpf in the medulla oblongata. Dopaminergic neurons 
were also observed in the locus coeruleus and furthermore 
in the posterior tuberculum that is localized in the dienceph-
alon (forebrain). Serotonergic neurons were also observed 
in the posterior tuberculum and by 32 hpf in the spinal cord 
as well.9,10 Finally, spatiotemporal expression of the zebraf-
ish opioid receptors shows a wide distribution in the central 
nervous system at 24 and 48 hpf.11,12 The early establish-
ment of the main neurotransmission systems before and by 
the time of PMR initiation is in accordance with the pheno-
typical clusters we could detect. Moreover, the early amin-
ergic innervation of the spinal cord by the hindbrain, which 
is described in a study by McLean and Fetcho,9 is in line 
with the sudden shift in motor behavior from low-frequency 
touch responses until 26 hpf to high-frequency swimming 
from 28 hpf onward.8 This swimming behavior is involved 
in the PMR and was shown to be driven by photosensitive 
hindbrain neurons.5
Expression studies have also demonstrated the early 
presence of adenosine,13 purinergic,14,15 and melatonin16 
receptors in the central nervous system of the developing 
zebrafish embryo at 24 hpf. This is in line with the identifi-
cation of multiple PMR positive molecules from these 
receptor classes. We also identified PMR positive molecules 
that act through histamine or sigma receptors, suggesting 
their functionality at these early stages. The presence of 
these receptors in the central nervous system at 30 hpf has 
not yet been reported, to our knowledge, as only few studies 
have been done that did not include spatiotemporal investi-
gations at this early stage.17–19
Furthermore, with this study a KNIME workflow was 
built to analyze behavioral data in a rapid and easy manner. 
The workflow is designed to calculate behavioral finger-
prints for hundreds—up to thousands—of treatments at the 
same time, and finally to hierarchically cluster these finger-
prints. This workflow enables everyone, without the need 
for programming skills or IT experience, to analyze behav-
ioral data. Parameters can easily be changed through the 
configuration button of each node; for example, the type of 
distance measure, the type of linkage, and the critical 
pseudo Z-score value can be changed. Moreover, the work-
flow is designed such that nodes can easily be removed, 
added, or changed to alter the type of analysis.
Finally, in this study we focused on the applicability of 
the photomotor response, which is a nonvisual light-driven 
behavioral response. Other types of behavioral responses to 
neuronal stimuli can also be used for neuroactive drug dis-
covery, for example, visual light-driven responses and audi-
tory responses. One example is the automated rest/wake 
behavioral assay that was reported by Rihel and colleagues 
for phenotype-based target prediction and drug discovery.20 
The challenge becomes to correlate these different types 
of neuronal responses in drug screening strategies. One 
possibility is to generate a battery of different behavioral 
assays and combine the results as different bars within a 
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descriptive barcode. Such an approach allows a more 
detailed level of phenotypic description and is expected to 
improve drug discovery and target prediction. This princi-
ple is referred to as behavioral barcoding and has been pre-
viously described.3
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